PMID- 34125923
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20231004
IS  - 1897-4279 (Electronic)
IS  - 0022-9032 (Linking)
VI  - 79
IP  - 5
DP  - 2021
TI  - Cost-effectiveness of telerehabilitation in patients with heart failure in 
      Poland: an analysis based on the results of Telerehabilitation in the Heart 
      Failure Patients (TELEREH-HF) randomized clinical trial.
PG  - 510-516
LID - 10.33963/KP.15885 [doi]
AB  - BACKGROUND: Telerehabilitation in the Heart Failure Patients (TELEREH-HF) study 
      showed a statistically significant improvement in the tertiary outcomes i.e. the 
      New York Heart Association (NYHA) class after a 9-week follow-up, consistent with 
      telerehabilitation-related benefits to quality of life (QoL) measured with the 
      36-item Short Form questionnaire (SF-36). AIMS: The study analyzed the 
      cost-effectiveness of hybrid telerehabilitation compared to standard care in 
      heart failure patients in the Polish setting using findings from the TELEREH-HF 
      trial. METHODS: Cost-utility analysis was conducted from the perspective of a 
      public payer (the Polish National Health Fund). The quality-adjusted life-year 
      (QALY) measure was based on QoL, as survival benefit was not confirmed in the 
      TELEREH-HF. Utility values were estimated based on NYHA improvement and a 
      systematic review of NYHA-specific utility values. Alternatively, SF-36 results 
      were translated into utility values. Telerehabilitation costs covered 8 weeks, 5 
      days/week, at a daily cost of 74 Polish zloty (PLN). Standard care costs resulted 
      from extra in-patient and out-patient rehabilitation costs incurred for selected 
      patients. A lifetime horizon was adopted, with an estimated average survival time 
      of 3.9 years based on 2 years TELEREH-HF follow-up and subsequent 
      literature-derived prognosis. RESULTS: Base case analysis yielded a 0.044 and 
      0.027 gain in QALY for the NYHA and SF-36-based approaches, corresponding to a 
      cost per QALY of 58.7 and 96 thousand PLN, respectively. Sensitivity analysis 
      confirmed that the cost per QALY value was likely below the official 
      cost-effectiveness threshold in Poland. CONCLUSIONS: The use of 
      telerehabilitation was found cost-effective in Poland, i.e., the clinical 
      benefits justify the additional costs.
FAU - Niewada, Maciej
AU  - Niewada M
AD  - Department of Experimental and Clinical Pharmacology, Medical University of 
      Warsaw, Warszawa, Poland.
AD  - HealthQuest, Warszawa, Poland.
FAU - Tabor, Bernadetta
AU  - Tabor B
AD  - HealthQuest, Warszawa, Poland.
FAU - Piotrowicz, Ewa
AU  - Piotrowicz E
AD  - Telecardiology Center, National Institute of Cardiology, Warszawa, Poland. 
      epiotrowicz@ikard.pl.
FAU - Piotrowicz, Ryszard
AU  - Piotrowicz R
AD  - National Institute of Cardiology, Warszawa, Poland.
AD  - Warsaw Academy of Medicine Rehabilitation, Warszawa, Poland.
FAU - Opolski, Grzegorz
AU  - Opolski G
AD  - 1st Department of Cardiology, Medical University of Warsaw, Warszawa, Poland.
FAU - Banach, Maciej
AU  - Banach M
AD  - Department of Hypertension, Medical University of Lodz, Lodz, Poland.
FAU - Jakubczyk, Michal
AU  - Jakubczyk M
AD  - HealthQuest, Warszawa, Poland.
AD  - SGH Warsaw School of Economics, Warszawa, Poland.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Kardiol Pol
JT  - Kardiologia polska
JID - 0376352
SB  - IM
CIN - Kardiol Pol. 2021;79(5):489-490. PMID: 34125919
MH  - Cost-Benefit Analysis
MH  - *Heart Failure
MH  - Humans
MH  - Poland
MH  - Quality of Life
MH  - Quality-Adjusted Life Years
MH  - Randomized Controlled Trials as Topic
MH  - *Telerehabilitation
OTO - NOTNLM
OT  - cost-effectiveness
OT  - heart failure
OT  - telerehabilitation
EDAT- 2021/06/15 06:00
MHDA- 2021/06/22 06:00
CRDT- 2021/06/14 17:30
PHST- 2021/06/08 00:00 [received]
PHST- 2021/06/08 00:00 [accepted]
PHST- 2021/06/14 17:30 [entrez]
PHST- 2021/06/15 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - VM/OJS/J/84083 [pii]
AID - 10.33963/KP.15885 [doi]
PST - ppublish
SO  - Kardiol Pol. 2021;79(5):510-516. doi: 10.33963/KP.15885.